Novartis (NVS -1.3%) and Microsoft (MSFT -0.3%) form a five-year partnership to use AI to design, personalize, and optimize the development of CAR-T cancer therapy.
Novartis is setting up the Novartis AI innovation
lab with Microsoft as the partner to bring together NVS data sets with
Microsoft’s AI solutions to create new models and applications. The lab
will also tackle computational challenges such as the optimization of
cell and gene therapies at scale.
Financial terms weren’t disclosed.
Sources: Press release / STAT report
https://seekingalpha.com/news/3502937-novartis-microsoft-team-ai-drug-development
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.